A low percentage of HER-2 amplification whereas indicates poor prognosis in salivary carcinoma ex pleomorphic adenoma: a study of 140 cases
A low percentage of HER-2 amplification whereas indicates poor prognosis in salivary carcinoma ex pleomorphic adenoma: a study of 140 cases
复制标题
HER-2 扩增比例较低，而表明多形性腺瘤以外的唾液癌预后较差：一项针对 140 例病例的研究
DOI：
10.1111/jop.12477
复制
发表时间：
2017
影响因子：
3.3
通讯作者：
Tian Zhen
中科院分区：
文献类型：
--
作者：
Xia Liang;Hu Yuhua;Li Jiang;Gu Ting;Zhang Chunye;Wang Lizhen;Tian Zhen
背景人表皮生长因子受体2（HER-2）在包括涎腺恶性肿瘤在内的多种恶性肿瘤中均有表达，HER-2靶向治疗已被应用于HER-2过表达肿瘤的治疗。本研究的目的是确定HER-2在涎腺浸润性癌不含多形性腺瘤（ICXPA）中的表达情况，为将来HER-2靶向治疗提供有力的支持。方法与结果收集了140例ICXPA患者的临床病理和随访资料。所有病例均通过免疫组化和荧光原位杂交基因扩增检测HER-2表达。研究表明，HER-2在所有病例中的阳性率仅为25%（35/140），但在有管腔分化的恶性成分的ICXPA中的阳性率（32/79，40.5%）明显高于无管腔分化的病例（3/61，4.9%）。HER-2过表达与性别、组织学分级和N分期密切相关，HER-2阳性肿瘤的总生存时间较短（P= 0.036）和疾病特异性生存时间短（P= 0.042）患者，结论人表皮生长因子受体2扩增与乳腺癌恶性成分的细胞分化显著相关。ICXPA和它意味着一个不利的预后。尽管HER-2阳性在肿瘤中并不常见，但HER-2阳性患者的靶向治疗仍值得期待。
BackgroundHuman epidermal growth factor receptor 2 (HER‐2) has been found in many malignant tumours including salivary malignancy.HER‐2‐targeted therapy has been applied in the treatment ofHER‐2‐overexpressing carcinoma. The aim of this study was to determine the status ofHER‐2in salivary invasive carcinoma ex pleomorphic adenoma (ICXPA) in a relatively large Chinese sample, which may provideHER‐2‐targeted therapy with profound support in the future.Methods and resultsWe collected 140 ICXPAs and their related clinicopathological and follow‐up data. All cases were examined forHER‐2expression by immunohistochemistry and gene amplification by fluorescencein situhybridization, if necessary. The study showed that the ratio ofHER‐2positivity was only 25% (35/140) in all cases, but the positive ratio in ICXPAs with luminal differentiation for malignant component (32/79, 40.5%) was much higher than that in cases with non‐luminal differentiation (3/61, 4.9%). The overexpression ofHER‐2was closely associated with gender, histological grade and N stage.HER‐2‐positive tumours conferred short overall survival time (P= 0.036) and short disease‐specific survival time (P= 0.042) in patients, butHER‐2status was not an independent predictor of prognosis.ConclusionsHuman epidermal growth factor receptor 2 amplification is significantly associated with cell differentiation of the malignant component in ICXPA and it implies an unfavourable prognosis. AlthoughHER‐2positivity is not common in the tumour,HER‐2‐targeted therapy for thoseHER‐2‐positive patients is still worth expecting.